Quality of life and social functioning during treatment of recent hepatitis C infection: A multi-centre prospective cohort

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Doyle, Joseph S ^a,b,c   Grebely, Jason ^d   Spelman, Tim ^a   Alavi, Maryam ^d   Matthews, Gail ^h   Thompson, Alexander J ^f,g   Dore, Gregory J ^d,e,h   Hellard, Margaret ^a   Kaldor, John ^h   Marks, Philippa ^h   Lloyd, Andrew ^h   Haber, Paul ⁱ   French, Rosemary ^a   White, Peter ^h   Rawlinson, William ^h   Day, Carolyn ^a   Van Beek, Ingrid ⁱ   McCaughan, Geoffrey ^j   Madden, Annie ^k   Dolan, Kate ^h   Farrell, Geoff ^l   Crofts, Nick ^m   Sievert, William ⁿ   Baker, David ^o   more..

^a BURNET INSTITUTE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f ST VINCENT S HOSPITAL   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ Burnet Institute ^*  (Australia)

^j ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^k Australian Injecting and Illicit Drug Users League   (Australia)

^l CANBERRA HOSPITAL   (Australia)

^m Nossal Institute   (Australia)

ⁿ MONASH MEDICAL CENTRE   (Australia)

^o East Sydney Doctors   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG ABUSE; DRUG RESPONSE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIXED INFECTION; MULTICENTER STUDY (TOPIC); OPIATE TREATMENT INDEX SOCIAL FUNCTIONING SCALE; PATIENT COMPLIANCE; QUALITY OF LIFE; SHORT FORM 12; SOCIAL INTERACTION; SUSTAINED VIROLOGICAL RESPONSE; AUSTRALIA; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MULTICENTER STUDY; NEEDLE SHARING; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PSYCHOLOGY; QUESTIONNAIRE; SUBSTANCE ABUSE;

ADULT; ANTIVIRAL AGENTS; AUSTRALIA; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; NEEDLE SHARING; PATIENT COMPLIANCE; PATIENT OUTCOME ASSESSMENT; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RIBAVIRIN; SUBSTANCE ABUSE, INTRAVENOUS; SURVEYS AND QUESTIONNAIRES;

EID: 84977482033     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150655     Document Type: Article

References (40)

1. De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Raiteri R, et al. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C. J Antimicrob Chemother. 2006; 57(2):360-3. PMID: 16396921.
2. Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol. 2005; 42(3):329-33. PMID: 15710214.
3. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006; 43(2):250-6. Epub 2006/01/28. doi: 10.1002/hep.21043 PMID: 16440367.
4. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001; 345(20):1452-7. Epub 2002/01/17. doi: 10.1056/NEJMoa011232 PMID: 11794193.
5. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, et al. Effective treatment of injecting drug users with recently acquired Hepatitis C virus Infection. Gastroenterology. 2010; 138:123-35. doi: 10.1053/j.gastro.2009.09.019 PMID: 19782085
6. Deterding K, Gruner N, Buggisch P, Wiegand J, Galle PR, Spengler U, et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis. 2013; 13(6):497-506. Epub 2013/03/26. doi: 10.1016/s1473-3099(13)70059-8 PMID: 23523674.
7. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002; 36:S237-44. PMID: 12407599
8. Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011; 8(4):212-23. doi: 10.1038/nrgastro.2011.21 PMID: 21386812
9. Reddy KR, Nelson DR, Zeuzem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J Hepatol. 2009; 50(2):402-11. Epub 2008/12/19. doi: 10.1016/j.jhep.2008.11.006 PMID: 19091439.
10. Grebely J, Matthews GV, Dore GJ. Treatment of acute HCV infection. Nat Rev Gastroenterol Hepatol. 2011; 8(5):265-74. doi: 10.1038/nrgastro.2011.32 PMID: 21423258
11. Hellard M, Doyle JS, Sacks-Davis R, Thompson AJ, McBryde E. Eradication of hepatitis C infection: The importance of targeting people who inject drugs. Hepatology. 2014; 59(2):366-9. doi: 10.1002/hep.26623 PMID: 23873507
12. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology. 2007; 45(3):806-16. doi: 10.1002/hep.21565 PMID: 17326207
13. Thein HH, Butler T, Krahn M, Rawlinson W, Levy MH, Kaldor JM, et al. The effect of hepatitis C virus infection on health-related quality of life in prisoners. J Urban Health. 2006; 83(2):275-88. Epub 2006/06/01. doi: 10.1007/s11524-005-9015-4 PMID: 16736376; PubMed Central PMCID: PMC2527173.
14. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007; 46(3):420-31. Epub 2007/01/02. doi: 10.1016/j.jhep.2006.10.009 PMID: 17196293; PubMed Central PMCID: PMC1995129.
15. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005; 41(4):790-800. Epub 2005/03/26. doi: 10.1002/hep.20659 PMID: 15791608.
16. Bjornsson E, Verbaan H, Oksanen A, Fryden A, Johansson J, Friberg S, et al. Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scandinavian journal of gastroenterology. 2009; 44(7):878-87. Epub 2009/05/14. doi: 10.1080/00365520902898135 PMID: 19437190.
17. Teuber G, Schafer A, Rimpel J, Paul K, Keicher C, Scheurlen M, et al. Deterioration of health-related quality of life and fatigue in patients with chronic hepatitis C: Association with demographic factors, inflammatory activity, and degree of fibrosis. J Hepatol. 2008; 49(6):923-9. Epub 2008/10/22. doi: 10.1016/j.jhep.2008.07.025 PMID: 18929420.
18. Karaivazoglou K, Iconomou G, Triantos C, Hyphantis T, Thomopoulos K, Lagadinou M, et al. Fatigue and depressive symptoms associated with chronic viral hepatitis patients. health-related quality of life (HRQOL). Ann Hepatol. 2010; 9(4):419-27. Epub 2010/11/09. PMID: 21057161.
19. Doyle JS, Sacks-Davis R, Hellard ME. Acute hepatitis C infection: new approaches to surveillance, treatment and prevention. Current Hepatitis Reports. 2012; 11(4):221-30.
20. Snow KK, Bonkovsky HL, Fontana RJ, Kim HY, Sterling RK, Di Bisceglie AM, et al. Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Alimentary pharmacology & therapeutics. 2010; 31(7):719-34. Epub 2010/01/15. doi: 10.1111/j.1365-2036.2010.04235.x PMID: 20070284; PubMed Central PMCID: PMC2923484.
21. Papastergiou V, Skorda L, Lisgos P, Hletsos M, Ketikoglou I, Zamanis C, et al. Health-related quality of life in patients with chronic hepatitis C. The impact of antiviral therapy. European Journal of Internal Medicine. 2011; 22:S46. doi: http://dx.doi.org/10.1016/S0953-6205%2811%2960190-8. PMID: 70559814.
22. John-Baptiste AA, Tomlinson G, Hsu PC, Krajden M, Heathcote EJ, Laporte A, et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. American Journal of Gastroenterology. 2009; 104(10):2439-48. doi: http://dx.doi.org/10.1038/ajg.2009.346. PMID: 2009565154. doi: 10.1038/ajg.2009.346
23. Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multidimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. British Journal of Addiction. 1992; 87(5):733-42. PMID: 1591524
24. Schulte B, Schütt S, Brack J, Isernhagen K, Deibler P, Dilg C, et al. Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance. Drug and alcohol dependence. 2010; 109(1-3):248-51. doi: http://dx.doi.org/10.1016/j.drugalcdep.2010.01.009. doi: 10.1016/j.drugalcdep.2010.01.009 PMID: 20167441
25. Alavi M, Grebely J, Matthews GV, Petoumenos K, Yeung B, Day C, et al. Effect of pegylated interferon-alpha-2a treatment on mental health during recent hepatitis C virus infection. J Gastroenterol Hepatol. 2012; 27(5):957-65. Epub 2011/12/07. doi: 10.1111/j.1440-1746.2011.07035.x PMID: 22142332; PubMed Central PMCID: PMCPMC3331928.
26. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007; 56(3):385-9. doi: 10.1136/gut.2006.099150 PMID: 17005764; PubMed Central PMCID: PMC1856823.
27. Gidding HF, Law MG, Amin J, Macdonald GA, Sasadeusz JJ, Jones TL, et al. Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Med J Aust. 2011; 194(8):398-402. Epub 2011/04/19. PMID: 21495939.
28. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry. 1998; 59 Suppl 20:22-33; quiz 4-57. Epub 1999/01/09. PMID: 9881538.
29. Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample. Br J Clin Psychol. 2005; 44(Pt 2):227-39. Epub 2005/07/12. doi: 10.1348/014466505x29657 PMID: 16004657.
30. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265):798-801. Epub 2009/09/18. doi: 10.1038/nature08463 PMID: 19759533; PubMed Central PMCID: PMC3172006.
31. Ware JE Jr., Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998; 51(11):903-12. Epub 1998/11/17. PMID: 9817107.
32. Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998; 51(11):1171-8. Epub 1998/11/17. PMID: 9817135.
33. Foster GR. Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat. 2009; 16(9):605-11. Epub 2009/08/14. doi: 10.1111/j.1365-2893.2009.01154.x PMID: 19674284.
34. Grebely J, Petoumenos K, Matthews GV, Haber P, Marks P, Lloyd AR, et al. Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Drug and alcohol dependence. 2010; 107(2-3):244-9. Epub 2009/11/21. doi: 10.1016/j.drugalcdep.2009.09.015 PMID: 19926405; PubMed Central PMCID: PMC2853739.
35. Grebely J, Matthews GV, Hellard M, Shaw D, van Beek I, Petoumenos K, et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol. 2011; 55(1):76-85. Epub 2010/12/15. doi: 10.1016/j.jhep.2010.10.033 PMID: 21145855; PubMed Central PMCID: PMC3117933.
36. Matthews GV, Hellard M, Haber P, Yeung B, Marks P, Baker D, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis. 2009; 48:650-8. doi: 10.1086/596770 PMID: 19191653
37. Rodrigue JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, et al. Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children. Hepatology. 2011; 53(5):1468-75. Epub 2011/02/26. doi: 10.1002/hep.24248 PMID: 21351116; PubMed Central PMCID: PMC3082614.
38. Dietze P, Stoove M, Miller P, Kinner S, Bruno R, Alati R, et al. The self-reported personal wellbeing of a sample of Australian injecting drug users. Addiction. 2010; 105(12):2141-8. Epub 2010/09/22. doi: 10.1111/j.1360-0443.2010.03090.x PMID: 20854337.
39. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis. 2005; 40 Suppl 5:S336-8. Epub 2005/03/16. doi: 10.1086/427449 PMID: 15768344.
40. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis. 2009; 49(4):561-73. Epub 2009/07/11. doi: 10.1086/600304 PMID: 19589081.